NVCT (Nuvectis Pharma, Inc.) — Stock Analysis, Catalysts & AI Research

Nuvectis Pharma, Inc.

$9.80

Health CareBiotechnology

The Read: 1% on confirming Phase 1 trial initiation for NUV-519, and gained about 6.

Price

Overlays

Panel

NVCT

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Nuvectis Pharma, Inc.

$9.80

Health CareBiotechnology

The Read: 1% on confirming Phase 1 trial initiation for NUV-519, and gained about 6.

Price

Overlays

Panel

NVCT

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Create your free account to unlock active Expected Moves for NVCT

Expected Moves

Nuvectis Pharma, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow

Create your free account to unlock active Expected Moves for NVCT

Expected Moves

Nuvectis Pharma, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow